Suppr超能文献

美国肝脏移植成本的不断上升。

The rising cost of liver transplantation in the United States.

作者信息

Kaplan Alyson, Winters Adam, Klarman Sharon, Kriss Michael, Hughes Dempsey, Sharma Pratima, Asrani Sumeet, Hutchison Alan, Myoung Paul, Zaman Asad, Butler Laura, Pomposelli James, Gordon Fredric, Duarte-Rojo Andres, Devuni Deepika, Fortune Brett

机构信息

Department of Surgery, Transplant Institute, Tufts Medical Center, Boston, Massachusetts, USA.

Recanati/Miller Transplantation Institute, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

出版信息

Liver Transpl. 2024 Sep 25. doi: 10.1097/LVT.0000000000000493.

Abstract

Liver transplantation (LT) is the only curative treatment for end-stage liver disease and significantly improves patient outcomes. However, LT is resource-intensive and costly, with expenditures rising dramatically in recent years. Factors contributing to this increase in cost include expanded transplant criteria, utilization of marginal organs, and broader organ distribution, resulting in significant logistical expenses. Advanced technologies like organ perfusion devices, while promising better outcomes, further inflate costs due to their high price and market monopolization. Moreover, living donor liver transplant and utilization of donation after cardiac death organs introduce higher initial expenditures yet potential long-term savings. Despite rising costs, reimbursement has remained largely stagnant, putting financial strain on transplant programs, and threatening their sustainability. This review examines the multifaceted drivers of rising costs in LT, focusing on recent policy changes, the role of organ procurement organizations, and the impact of new technologies. We also propose comprehensive solutions at national, organ procurement organization, and local levels, including optimizing resource allocation, leveraging regional collaborations, and advocating for revised reimbursement models to curb escalating costs. Addressing these challenges is critical to ensuring the continued viability of LT programs and maintaining patient access to this life-saving intervention.

摘要

肝移植(LT)是终末期肝病的唯一治愈性治疗方法,能显著改善患者预后。然而,肝移植资源密集且成本高昂,近年来费用急剧上升。导致成本增加的因素包括移植标准扩大、边缘器官的使用以及器官分配范围扩大,从而产生了大量后勤费用。像器官灌注设备这样的先进技术虽然有望带来更好的结果,但由于其高昂的价格和市场垄断,进一步推高了成本。此外,活体肝移植和心脏死亡后器官捐献的使用带来了更高的初始支出,但可能带来长期节省。尽管成本不断上升,但报销费用基本停滞不前,给移植项目带来了财务压力,并威胁到其可持续性。本综述探讨了肝移植成本上升的多方面驱动因素,重点关注近期政策变化、器官获取组织的作用以及新技术的影响。我们还在国家、器官获取组织和地方层面提出了全面的解决方案,包括优化资源分配、利用区域合作以及倡导修订报销模式以遏制成本不断上升。应对这些挑战对于确保肝移植项目的持续可行性以及维持患者获得这种挽救生命的干预措施至关重要。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验